The use of cDC1 in a therapeutic research context is still in the beginning stage, yet the perspective of exploiting this DC subset to improve anti-tumor immunotherapy is extremely encouraging and validation in future clinical trials is highly anticipated. This evidence concerns the gene MPPE1 and neoplasm.